Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
ZEN003694 + Talazoparib for Ovarian Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing a combination of two oral drugs, ZEN003694 and talazoparib, in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. ZEN003694 helps stop cancer cells from growing, while talazoparib blocks an enzyme that cancer cells need to repair themselves. The goal is to see how well these drugs work together in this specific group of patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service